Kimia Biosciences Limited

Teneligliptin Hydrobromide Hydrate

General Information:

Teneligliptin Hydrobromide Hydrate has been investigated for the treatment of Type 2 Diabetes Mellitus. This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha-amino acids. It is a long-acting, orally bioavailable, pyrrolidine-based inhibitor of dipeptide peptidase 4 (DPP-4), with hypoglycemic activity. Teneligliptin may also reduce plasma triglyceride levels through a sustained increase in GLP-1 levels. It is a vast growing molecule in the Indian market. Kimia Biosciences Ltd is one of the best Teneligliptin Hydrobromide Hydrate Manufacturers and Suppliers in India.

CAS No.

1572583-29-9

Therapeutic Category:

Anti-Diabetic

IUPAC Name:

[(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone;hydrate;pentahydrobromide

Molecular Formula:

C44H67Br5N12O3S2

Molecular Weight:

C44H67Br5N12O3S2

Molecular Structure:

Teneligliptin Hydrobromide Hydrate

Mechanism of Action

Teneligliptin acts on Incretin hormones, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released from enteroendocrine cells and enhance insulin secretion. Incretins are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), and have a very short half-life (t1/2) as a result. DPP-4 inhibitors increase the levels of active GLP-1 and GIP by inhibiting DPP-4 enzymatic activity; thus, in patients with diabetes, these inhibitors improve hyperglycemia in a glucose-dependent manner by increasing serum insulin levels and decreasing serum glucagon levels. Therefore, incretin-related agents such as DPP-4 inhibitors are promising drugs that can decrease glucose fluctuations in diabetic patients and have emerged as a new class of antidiabetic.